Camlin Fine Sciences Limited (CFSL) has issued a corrigendum to its postal ballot notice dated September 29, 2025, providing additional clarifications requested by the BSE and NSE regarding a proposed preferential issue of equity shares. This move comes as part of CFSL's strategic acquisition of a majority stake in French company Vinpai.

Key Details of the Preferential Issue

CFSL plans to issue 41,06,181 equity shares at ₹247.69 per share as consideration for acquiring a 78.68% stake in Vinpai through a share swap arrangement. The total consideration for the acquisition is €98.03 million, equivalent to approximately ₹101.71 crore.

Vinpai: A Strategic Acquisition

Vinpai, founded in 2011, is an 'ingredien'tech' company specializing in algae, plant, mineral, and fiber-based functional ingredients. The company offers natural alternatives to chemical additives for the food, cosmetics, and nutraceutical industries. In 2024, Vinpai generated revenues of €9.2 million, with over 70% from exports to more than 36 countries.

Share Swap Details

The following table outlines the share swap arrangement:

Impact on Shareholding

Post-issue, the new shareholders from Vinpai will collectively hold 2.10% of CFSL's expanded share capital. The promoter and promoter group holding is expected to decrease slightly from 49.08% to 47.08%, while public shareholding will increase from 50.92% to 52.92%.

Strategic Rationale

The acquisition of Vinpai is expected to enhance CFSL's product offerings, fostering innovation and competitiveness in the global market. It opens up new product ranges in the natural space and provides access to exciting markets, potentially leading to expansion of revenues and margins.

Regulatory Compliance

CFSL has obtained a valuation report from Sundae Capital Advisors Private Limited, an independent registered valuer, to comply with SEBI regulations. The company has also granted members who have already voted an opportunity to update their votes based on the additional information provided in the corrigendum, with submissions accepted until October 29, 2025.

This strategic move by Camlin Fine Sciences Limited represents a significant step towards expanding its presence in the natural ingredients market, potentially strengthening its position in the global food and nutraceutical industry.

Camlin Fine Sciences Limited has announced a crucial board meeting scheduled for September 29, 2025, to deliberate on a significant strategic move. The company is set to consider issuing equity shares through preferential allotment as part of a share swap arrangement, aiming to acquire a majority stake in Vinpai S.A.

Key Highlights

• Board Meeting Date: September 29, 2025
• Purpose: To consider and potentially approve the issuance of equity shares via preferential allotment
• Acquisition Target: Majority stake in Vinpai S.A.
• Method: Share swap arrangement
• Approval Process: Subject to shareholder approval through postal ballot

Trading Window Closure

In compliance with regulatory requirements, Camlin Fine Sciences has implemented a trading window closure:

• Closure Period: September 24, 2025, until 48 hours after the board meeting concludes
• Applicable to: Insiders, designated persons, and their immediate relatives

Background and Regulatory Compliance

The upcoming board meeting is a continuation of Camlin Fine Sciences' strategic plans, following previous disclosures made in February and June 2025 regarding the Vinpai acquisition. The company has emphasized that the proposed preferential issue for the share swap will be conducted in accordance with:

• The Companies Act, 2013, and its associated rules
• Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
• Other applicable laws and regulatory approvals

Shareholder Approval Process

If the board approves the proposal, Camlin Fine Sciences intends to initiate a postal ballot process to seek shareholder approval for the preferential issue related to the share swap. This step underscores the company's commitment to transparent corporate governance and shareholder engagement in major strategic decisions.

Market Implications

The proposed acquisition of a majority stake in Vinpai S.A. through a share swap arrangement could potentially strengthen Camlin Fine Sciences' market position and expand its operational capabilities. Investors and market analysts will be closely watching the outcome of the September 29 board meeting and the subsequent shareholder approval process.

Stakeholders are advised to stay tuned for further updates and official announcements from the company regarding the progress of the Vinpai acquisition and its potential impact on Camlin Fine Sciences' future growth trajectory.